Finerenone vs HRS-1780

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Chronic Kidney Disease

Shared mechanism: Mineralocorticoid receptor · full Chronic Kidney Disease pipeline

Finerenone · Kerendia

Marketed by Bayer

Approved in Chronic Kidney Diseasesmall molecule
Reliable signal

NCT02540993 · Phase 3 · completed

The trial was randomized, quadruple-blind, placebo-controlled, and large, with 5,734 participants randomized nearly equally between finerenone and placebo. Its hard clinical kidney endpoint was met: 504 participants receiving finerenone versus 600 receiving placebo experienced the primary outcome, with a statistically significant hazard ratio of 0.825 (p=0.0014).

Next expected readout: November 2026 · NCT06954090 (registry estimate)

Reported efficacy

Mean rate of change as measured by the total slope of eGFR from baseline to Month-32. (From baseline to month 32): Total eGFR slope, baseline to month 32 (FIND-CKD): -3.3 mL/min/1.73m2/year finerenone vs -4.0 mL/min/1.73m2/year placebo; between-group difference 0.7 mL/min/1.73m2/year (95% CI 0.3-1.1; p<0.001) (met)

Result source: NCT05047263

HRS-1780

Developed by Jiangsu Hengrui Pharmaceuticals

Phase 3 in Chronic Kidney Diseasesmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: April 2030 · NCT07419828 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Chronic Kidney Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointFinerenoneHRS-1780
Kidney composite outcome—Not posted · NCT05047263—Trial running · NCT07419828
UACR, % change—Not posted · NCT05047263—Trial running · NCT07419828
eGFR slope—Not posted · NCT05047263—Trial running · NCT07419828
Haemoglobin, change—Not posted · NCT05047263—Trial running · NCT07419828

Kidney composite outcome

Finerenone
—Not posted · NCT05047263
HRS-1780
—Trial running · NCT07419828

UACR, % change

Finerenone
—Not posted · NCT05047263
HRS-1780
—Trial running · NCT07419828

eGFR slope

Finerenone
—Not posted · NCT05047263
HRS-1780
—Trial running · NCT07419828

Haemoglobin, change

Finerenone
—Not posted · NCT05047263
HRS-1780
—Trial running · NCT07419828
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

HRS-1780: no structured comparison results are available for Chronic Kidney Disease.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Finerenone: 4 of 4 rows · HRS-1780: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricFinerenone
Dropout rate
1.5%a
NCT02540993 · Phase 3 · monotherapy · Chronic Kidney Disease, Type 2 Diabetes · phase 3
show 10 more results
—Finerenone + Empagliflozin Group
NCT05254002 · Phase 2 · registry result, not featured evidence · combination
—Finerenone Group
NCT05254002 · Phase 2 · registry result, not featured evidence
12.1%Finerenone and Empagliflozin
NCT05254002 · Phase 2 · registry result, not featured evidence
1%
NCT05013008 · Phase 2 · registry result, not featured evidence
21.2%10-20 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence
24.8%15-20 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence
30.1%2.5-5 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence
26.1%5-10 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence
27.2%7.5-15 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence
—2.5-5 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
—a
NCT02540993 · Phase 3 · monotherapy · Chronic Kidney Disease, Type 2 Diabetes · phase 3
show 10 more results
—Finerenone + Empagliflozin Group
NCT05254002 · Phase 2 · registry result, not featured evidence · combination
—Finerenone Group
NCT05254002 · Phase 2 · registry result, not featured evidence
4.8%Finerenone and Empagliflozin
NCT05254002 · Phase 2 · registry result, not featured evidence
—
NCT05013008 · Phase 2 · registry result, not featured evidence
10.6%10-20 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence
12.7%15-20 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence
12.7%2.5-5 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence
15.8%5-10 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence
14.8%7.5-15 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence
—2.5-5 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence
Serious AEs
31.9%a
NCT02540993 · Phase 3 · monotherapy · Chronic Kidney Disease, Type 2 Diabetes · phase 3
show 10 more results
7.1%Finerenone + Empagliflozin Group
NCT05254002 · Phase 2 · registry result, not featured evidence · combination
6.1%Finerenone Group
NCT05254002 · Phase 2 · registry result, not featured evidence
—Finerenone and Empagliflozin
NCT05254002 · Phase 2 · registry result, not featured evidence
—
NCT05013008 · Phase 2 · registry result, not featured evidence
27.2%10-20 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence
35%15-20 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence
—2.5-5 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence
28.8%5-10 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence
31.1%7.5-15 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence
41.9%2.5-5 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
a
hyperkalaemia 14.9% (placebo 7.5%)
nasopharyngitis 8.5% (placebo 8.8%)
anaemia 7.1% (placebo 6.3%)
NCT02540993 · Phase 3 · monotherapy · Chronic Kidney Disease, Type 2 Diabetes · phase 3
show 7 more results
hyperkalaemia 9.3%
glomerular filtration rate decreased 6.3%
diarrhoea 3.4%
NCT05254002 · Phase 2 · registry result, not featured evidence · combination
hyperkalaemia 10.2%
glomerular filtration rate decreased 4.2%
diarrhoea 3.4%
NCT05254002 · Phase 2 · registry result, not featured evidence
10-20 mg OD
hypokalaemia 8.3%
renal impairment 4.7%
cardiac failure 4.1%
NCT01807221 · Phase 2 · registry result, not featured evidence
15-20 mg OD
hypokalaemia 10.4%
cardiac failure 6.1%
dyspnoea 6.1%
NCT01807221 · Phase 2 · registry result, not featured evidence
5-10 mg OD
hypokalaemia 12.9%
hypotension 6.7%
cardiac failure 6.1%
NCT01807221 · Phase 2 · registry result, not featured evidence
7.5-15 mg OD
hypokalaemia 9%
hypotension 6.6%
diarrhoea 6%
NCT01807221 · Phase 2 · registry result, not featured evidence
2.5-5 mg OD
hypokalaemia 11.6%
cardiac failure 8.1%
dyspnoea 7%
NCT01807221 · Phase 2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for 10 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Finerenone

Renal Composite Endpoint 40 17.8% (n=2833) vs 21.1% (n=2841) placebo
event count · % of participants
NCT02540993 · Phase 3 · monotherapy · Chronic Kidney Disease, Type 2 Diabetes · phase 3 · converted to % from 504 Participants as posted
MACE HHF Composite 13% (n=2833) vs 14.8% (n=2841) placebo
event count · % of participants
NCT02540993 · Phase 3 · monotherapy · Chronic Kidney Disease, Type 2 Diabetes · phase 3 · converted to % from 367 Participants as posted
UACR 0.655 vs 0.952 placebo ratio @ 16wk
ratio to baseline · ratio
NCT02540993 · Phase 3 · monotherapy · Chronic Kidney Disease, Type 2 Diabetes · phase 3
show 3 more results
0.483 vs 0.708 Empagliflozin ratio @ 25.7wk
NCT05254002 · Phase 2 · registry result, not featured evidence
0.483 vs 0.683 Finerenone ratio @ 25.7wk
NCT05254002 · Phase 2 · registry result, not featured evidence
0.818 vs 0.853 Finerenone ratio @ 30wk
NCT05254002 · Phase 2 · registry result, not featured evidence
Renal Composite Endpoint 57 8.9% (n=2833) vs 11.5% (n=2841) placebo
event count · % of participants
NCT02540993 · Phase 3 · monotherapy · Chronic Kidney Disease, Type 2 Diabetes · phase 3 · converted to % from 252 Participants as posted
eGFR 30% Decline 6.3% (n=268) vs 3.8% (n=264) Finerenone @ 4.3wk
event count · % of participants
NCT05254002 · Phase 2 · registry result, not featured evidence · converted to % from 17 Participants as posted
NT-proBNP 30% Reduction 30.9% (n=162) vs 37.2% (n=207) Eplerenone @ 12.857wk2.5-5 mg OD
responder rate · % of participants
NCT01807221 · Phase 2 · registry result, not featured evidence
show 4 more results
32.5% (n=157) vs 37.2% (n=207) Eplerenone @ 12.857wk5-10 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence
37.3% (n=158) vs 37.2% (n=207) Eplerenone @ 12.857wk7.5-15 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence
38.8% (n=160) vs 37.2% (n=207) Eplerenone @ 12.857wk10-20 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence
34.2% (n=158) vs 37.2% (n=207) Eplerenone @ 12.857wk15-20 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence
CV Hospitalization 14.2% (n=162) vs 13.5% (n=207) Eplerenone @ 4.29wk2.5-5 mg OD
event count · % of participants
NCT01807221 · Phase 2 · registry result, not featured evidence · converted to % from 23 Participants as posted
show 14 more results
8.9% (n=157) vs 13.5% (n=207) Eplerenone @ 4.29wk*5-10 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence · converted to % from 14 Participants as posted
5.1% (n=158) vs 13.5% (n=207) Eplerenone @ 4.29wk*7.5-15 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence · converted to % from 8 Participants as posted
4.4% (n=160) vs 13.5% (n=207) Eplerenone @ 4.29wk*10-20 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence · converted to % from 7 Participants as posted
9.5% (n=158) vs 13.5% (n=207) Eplerenone @ 4.29wk*15-20 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence · converted to % from 15 Participants as posted
20.4% (n=162) vs 20.8% (n=207) Eplerenone @ 8.57wk*2.5-5 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence · converted to % from 33 Participants as posted
14.6% (n=157) vs 20.8% (n=207) Eplerenone @ 8.57wk*5-10 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence · converted to % from 23 Participants as posted
13.3% (n=158) vs 20.8% (n=207) Eplerenone @ 8.57wk*7.5-15 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence · converted to % from 21 Participants as posted
9.4% (n=160) vs 20.8% (n=207) Eplerenone @ 8.57wk*10-20 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence · converted to % from 15 Participants as posted
14.6% (n=158) vs 20.8% (n=207) Eplerenone @ 8.57wk*15-20 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence · converted to % from 23 Participants as posted
21.6% (n=162) vs 21.7% (n=207) Eplerenone @ 12.86wk*2.5-5 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence · converted to % from 35 Participants as posted
16.6% (n=157) vs 21.7% (n=207) Eplerenone @ 12.86wk*5-10 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence · converted to % from 26 Participants as posted
18.4% (n=158) vs 21.7% (n=207) Eplerenone @ 12.86wk*7.5-15 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence · converted to % from 29 Participants as posted
13.8% (n=160) vs 21.7% (n=207) Eplerenone @ 12.86wk*10-20 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence · converted to % from 22 Participants as posted
17.7% (n=158) vs 21.7% (n=207) Eplerenone @ 12.86wk*15-20 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence · converted to % from 28 Participants as posted
CV Hospitalization 26.5% (n=162) vs 27.1% (n=207) Eplerenone2.5-5 mg OD
event count · % of participants
Follow-up
NCT01807221 · Phase 2 · registry result, not featured evidence · converted to % from 43 Participants as posted
show 4 more results
24.2% (n=157) vs 27.1% (n=207) Eplerenone*5-10 mg OD
Follow-up
NCT01807221 · Phase 2 · registry result, not featured evidence · converted to % from 38 Participants as posted
22.8% (n=158) vs 27.1% (n=207) Eplerenone*7.5-15 mg OD
Follow-up
NCT01807221 · Phase 2 · registry result, not featured evidence · converted to % from 36 Participants as posted
16.9% (n=160) vs 27.1% (n=207) Eplerenone*10-20 mg OD
Follow-up
NCT01807221 · Phase 2 · registry result, not featured evidence · converted to % from 27 Participants as posted
21.5% (n=158) vs 27.1% (n=207) Eplerenone*15-20 mg OD
Follow-up
NCT01807221 · Phase 2 · registry result, not featured evidence · converted to % from 34 Participants as posted
KCCQ Clinical Summary 18.2 vs 20.5 Eplerenone score @ 4.29wk2.5-5 mg OD
absolute change · score
NCT01807221 · Phase 2 · registry result, not featured evidence
show 9 more results
19.3 vs 20.5 Eplerenone score @ 4.29wk5-10 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence
23 vs 20.5 Eplerenone score @ 4.29wk7.5-15 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence
24.9 vs 20.5 Eplerenone score @ 4.29wk10-20 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence
20.6 vs 20.5 Eplerenone score @ 4.29wk15-20 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence
21.3 vs 24.3 Eplerenone score @ 12.86wk2.5-5 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence
24.5 vs 24.3 Eplerenone score @ 12.86wk5-10 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence
29.3 vs 24.3 Eplerenone score @ 12.86wk7.5-15 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence
28.3 vs 24.3 Eplerenone score @ 12.86wk10-20 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence
22.2 vs 24.3 Eplerenone score @ 12.86wk15-20 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence
EQ-5D Index 0.02 vs 0.06 Eplerenone score @ 4.29wk2.5-5 mg OD
absolute change · score
NCT01807221 · Phase 2 · registry result, not featured evidence
show 9 more results
0.02 vs 0.06 Eplerenone score @ 4.29wk5-10 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence
0.07 vs 0.06 Eplerenone score @ 4.29wk7.5-15 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence
0.06 vs 0.06 Eplerenone score @ 4.29wk10-20 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence
0.02 vs 0.06 Eplerenone score @ 4.29wk15-20 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence
0.03 vs 0.08 Eplerenone score @ 12.86wk2.5-5 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence
0.04 vs 0.08 Eplerenone score @ 12.86wk5-10 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence
0.08 vs 0.08 Eplerenone score @ 12.86wk7.5-15 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence
0.1 vs 0.08 Eplerenone score @ 12.86wk10-20 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence
0.06 vs 0.08 Eplerenone score @ 12.86wk15-20 mg OD
NCT01807221 · Phase 2 · registry result, not featured evidence
EQ-5D Index 0.01 vs 0.06 Eplerenone score2.5-5 mg OD
absolute change · score
Follow-up
NCT01807221 · Phase 2 · registry result, not featured evidence
show 4 more results
0.01 vs 0.06 Eplerenone score5-10 mg OD
Follow-up
NCT01807221 · Phase 2 · registry result, not featured evidence
0.08 vs 0.06 Eplerenone score7.5-15 mg OD
Follow-up
NCT01807221 · Phase 2 · registry result, not featured evidence
0.07 vs 0.06 Eplerenone score10-20 mg OD
Follow-up
NCT01807221 · Phase 2 · registry result, not featured evidence
0.04 vs 0.06 Eplerenone score15-20 mg OD
Follow-up
NCT01807221 · Phase 2 · registry result, not featured evidence

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Finerenone's landscape · HRS-1780's landscape